United States News All stories

Bit Digital (NASDAQ:BTBT), a high-performance computing and digital asset mining company, has released its monthly treasury and staking update for March 2026, highlighting a significant Ethereum position and active yield-generation strategy.

Halozyme Therapeutics (NASDAQ:HALO) and Vertex Pharmaceuticals (NASDAQ:VRTX) announced a global exclusive collaboration and license agreement on April 7, 2026, aimed at leveraging Halozyme’s proprietary Hypercon™ microparticle technology to transform the delivery of biologic therapies.

Alzamend Neuro (NASDAQ:ALZN), a clinical-stage biopharmaceutical company focused on developing novel products for neurological disorders, reported preliminary pharmacodynamic data on April 7, 2026, from a healthy-subject study evaluating its lead candidate, AL001.

Booz Allen Hamilton (NYSE:BAH) announced on April 7, 2026, the successful completion of its acquisition of Defy Security, a move aimed at consolidating its position as a dominant provider of high-speed, tech-enabled cybersecurity services for both commercial and government sectors.

Academy Sports + Outdoors (NASDAQ:ASO) issued a preliminary sales update for the first quarter of fiscal 2026 on April 7, 2026, signaling a robust start to the year ahead of its scheduled Analyst Day in Katy, Texas.

Shares of ASML Holding (NYSE:ASML) declined on Tuesday as investors reacted to a new legislative proposal from U.S. lawmakers that could significantly tighten restrictions on the company’s ability to sell and service advanced chipmaking equipment in China.

Anthropic has entered into a massive infrastructure agreement with Google (NASDAQ:GOOGL) and Broadcom (NASDAQ:AVGO) to secure approximately 3.5 gigawatts of computing capacity, marking one of the largest hardware commitments in the history of the artificial intelligence industry.

NervGen Pharma (NASDAQ:NGEN), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system repair, has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), gaining alignment on the design of its Phase 3 registrational study, RESTORE.

Aris Mining (NYSE:ARIS) reported record gold revenue of more than $360 million for the first quarter ended March 31, 2026, driven by rising production levels and an unprecedented surge in realized gold prices.

Artivion (NYSE:AORT), a leading cardiac and vascular surgery company, announced on April 7, 2026, that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the NEXUS™ Aortic Arch System.

Precigen (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of gene and cell therapies, has announced a significant acceleration in the commercial rollout of PAPZIMEOS™ (zopapogene imadenovec-drba), projecting first-quarter 2026 revenue to exceed $18 million.

Soleno Therapeutics (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel treatments for rare diseases, announced on April 7, 2026, that it has voluntarily withdrawn its Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) for VIOKAT prolonged-release tablets.

MarketAxess Holdings (NASDAQ:MKTX), the operator of a leading electronic trading platform for fixed-income securities, reported record total credit average daily volume (ADV) for both March 2026 and the first quarter ended March 31, 2026, driven by a surge in portfolio and block trading activity.

Bluejay Diagnostics (NASDAQ:BJDX), a medical technology firm specializing in rapid near-patient testing, announced on April 7, 2026, that it has successfully enrolled 624 patients in its pivotal SYMON-II clinical trial.

Nuvalent (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, announced on April 7, 2026, the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for neladalkib.

Ascendis Pharma (NASDAQ:ASND) has officially commenced the commercial launch of YUVIWEL® (navepegritide) in the United States, marking the availability of the first once-weekly treatment for pediatric patients with achondroplasia.

Greenwich LifeSciences (NASDAQ:GLSI), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences, has filed new patent claims that could significantly expand the addressable market for its lead candidate, GLSI-100.

Lifezone Metals (NYSE:LZM) has announced the first successful production of platinum, palladium, and rhodium from U.S.-sourced spent automotive catalytic converters, marking a technical milestone for its proprietary Hydromet Technology.

Pony.ai (NASDAQ:PONY), a global leader in autonomous driving technology, has reached a critical milestone in its international commercialization roadmap, receiving regulatory approval on April 7, 2026, to begin "by-invite" autonomous rides in Singapore.

Pershing Square, led by billionaire investor Bill Ackman, has proposed a transformative merger between its acquisition vehicle and Universal Music Group (UMG) to relocate the world’s largest music label’s primary listing to the New York Stock Exchange.

Organogenesis Holdings (NASDAQ:ORGO), a leader in regenerative medicine, has announced positive topline results from a prospective, multi-center randomized controlled trial (RCT) evaluating PuraPly AM for the treatment of diabetic foot ulcers (DFUs).

Telix Pharmaceuticals (NASDAQ:TLX), a global leader in radiopharmaceutical precision medicine, has reported Q1 2026 group revenue of $230 million, representing a 24% increase over the same period last year and an 11% sequential rise from the previous quarter.

Deere & Company (NYSE:DE) has reached a definitive agreement to resolve a consolidated multidistrict "right to repair" lawsuit, agreeing to pay $99 million into a class settlement fund for eligible farmers and ranchers.

Mesoblast (NASDAQ:MESO), a global leader in allogeneic cellular medicines, has reported net sales of $30.3 million for its flagship product, Ryoncil (remestemcel-L-rknd), for the third fiscal quarter ended March 31, 2026.